Stanton Gerson, MD

Stanton Gerson, MD, is dean of the Case Western Reserve University (CWRU) School of Medicine with faculty at University Hospitals (UH), the Cleveland Veterans Affair Hospital, MetroHealth Medical Center and Cleveland Clinic. He is the Asa and Patricia Shiverick–Jane Shiverick (Tripp) Professor of Hematological Oncology and a CWRU Distinguished University Professor. He is also the Director of the National Center for Regenerative Medicine located at CWRU in Cleveland. Previously, he was the director of the NCI designated Case Comprehensive Cancer Center (Case CCC) and served as President of the Association of American Cancer Institutes in 2017-2019.

Dr. Gerson received his BA from Harvard College, his MD degree from Harvard Medical School, and completed his residency and fellowship in hematology-oncology at the Hospital of the University of Pennsylvania. He joined CWRU in 1983.

His research is focused on DNA repair mechanisms as targets for anti-cancer therapy, stem cell biology and use of stem cells in multiple therapies, including the first clinical trials in mesenchymal stem cells, cellular gene therapy, and development of early phase clinical trials for cancer. Four of his patented inventions have resulted in clinical therapeutics in ongoing clinical trials. He has over 260 publications and has co-edited two medical textbooks in cancer gene therapy and clinical hematology.

Inventions and patents have been licensed to a number of firms including Novartis, Lentigen and Myltenyi, Osiris Therapeutics and Mesoblast, Tracon Pharmaceuticals, Rodeo Therapeutics and Amgen. Dr. Gerson has served on scientific advisory boards for Tracon, Lentigen, Athersys and Attenuon, and on mock advisory boards for a number of pharmaceutical firms seeking FDA review.